Clinical Trials: Page 147
-
Sanofi, Merrimack continue development of molecular target found in many cancers
An extensive phase II clinical trial program is underway.
By Nicole Gray • June 22, 2014 -
Companies collaborate to fight multidrug-resistant pathogens
A new diagnostic test is available in Europe and coming to the U.S., but that's just the first step.
By Nicole Gray • June 22, 2014 -
Explore the Trendline➔
Getty Images
TrendlineOncology's research boom
More than one quarter of the medcines cleared by the FDA's main review office since 2015 have been cancer drugs, a tally that reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.
By BioPharma Dive staff -
NICE approves Effient for broader use
The product is now acceptable for treatment of many types of acute coronary syndrome.
By Nicole Gray • June 22, 2014 -
Sivextro approved for hard-to-treat skin infections
This is the second drug covered under the FDA's new Qualified Infectious Disease Program designation.
By Nicole Gray • June 22, 2014 -
Deep Dive
Theory can outrun reality on drug approval fast track
The designation can create a buzz that is often not justified.
By Nicole Gray • June 20, 2014 -
J&J rachets up R&D through 12 new alliances
The company has many collaborations underway.
By Nicole Gray • June 20, 2014 -
J&J acquires global rights to influenza drug
If approved, the vaccine would be a new treatment approach to an age-old viral condition.
By Nicole Gray • June 20, 2014 -
Takeda halts development of prostate cancer drug
Phase III trials showed increased progression-free survival, but no significant increases in overall survival.
By Nicole Gray • June 20, 2014 -
PhRMA highlights clinical development of drugs aimed at older Americans
For people over 65, 95% of healthcare spending is for chronic diseases.
By Nicole Gray • June 20, 2014 -
Bellerophon Therapeutics moves PAH treatment into phase II
This add-on therapy could help patients who need additional support despite receiving standard-of-care treatment.
By Nicole Gray • June 20, 2014 -
Pfizer expands immuno-oncology research through Cellectics parnership
Pfizer is expanding oncology research by collaborating with Cellectics, which brings a unique immuno-oncology research platform to the partnership.
By Nicole Gray • June 19, 2014 -
NICE: More novel anticoagulant use could reduce strokes
The British agency has recommended adding novel anticoagulants to formularies throughout the UK.
By Nicole Gray • June 18, 2014 -
Gardasil approved in EU for prevention of anal cancer
The drug now has an expanded therapeutic role in Europe that also includes HPV prevention in adolescents.
By Nicole Gray • June 18, 2014 -
Pfizer, Novartis push for approval of meningitis vaccines
The two companies each have developed a vaccine to prevent a virulent form of meningitis.
By Nicole Gray • June 18, 2014 -
Pfizer expands research capacity with Cambridge, MA location
The firm is setting up a mega-research facility, bringing together industry, academic and the hospital system to collaborate on therapeutic innovation.
By Nicole Gray • June 18, 2014 -
New prescription erectile dysfunction cream introduced to UK
Vitaros (alprostadil cream) is the first cream available for treating erectile function.
By Nicole Gray • June 18, 2014 -
JNJ partners with Viiv to create new combo HIV drug
The medication could end up rivaling Atripla.
By Nicole Gray • June 17, 2014 -
Study: No apparent benefit in reducing blood pressure below 'normal' range
The massive survey followed more than 4,400 people over two-plus decades.
By Randy Lilleston • June 17, 2014 -
Intarcia presents positive phase III data on a once-yearly diabetes drug
The new therapy may be the key to controlling high blood sugar levels. Intarcia presented positive data at ADA 2014.
By Nicole Gray • June 17, 2014 -
Sanofi, Medtronic team up to offer options for diabetes patients
The new partnership focuses on innovative drug-device breakthroughs.
By Nicole Gray • June 17, 2014 -
OncoMed halts phase I studies of cancer drugs, but aims to reinitiate
Ths company, which is testing a novel approach to treating cancer at the stem-cell level, is determined to continue development.
By Nicole Gray • June 17, 2014 -
Insulin 300 performs well in phase III trials
Will it beat its competitors?
By Nicole Gray • June 17, 2014 -
Deep Dive
As diabetes soars, so do research and treatment options
Currently, about 180 drugs are in development to address the diabetes-related challenges that persist despite available treatments.
By Nicole Gray • June 16, 2014 -
NICE reverses stance on skin cancer treatment after reviewing new survival data
The panel changed its decision of four months ago based on positive survival data extending out three years.
By Nicole Gray • June 16, 2014 -
Parion, Santen bring dry eye drug to Asian markets
The drug has a novel mode of action and will help Parion build an Asian distribution network with a new partner.
By Nicole Gray • June 13, 2014
Previous
